The Anticonvulsant Activity of Mucoadhesive Buccal Films of Sodium Valproate in Pentylenetetrazole-Induced Seizure Rat Model

Autor: Iwan Setiawan, Anas Subarnas, Yoga Windhu Wardhana
Rok vydání: 2022
Předmět:
DOI: 10.5281/zenodo.7537056
Popis: Buccal preparations are currently gaining interest in the study of drug delivery systems. These preparations can adhere to mucosal surfaces, hydrate, and deliver the drug across the buccal membrane. Based on the Biopharmaceutics Drug Disposition Classification System (BDDCS), the drug compound Sodium valproate Sodium valproate belongs to class 1 which has excellent solubility and permeability. Therefore, by developing into a mucoadhesive buccal dosage form, a faster onset of action will be obtained, increased bioavailability and ease of use. In partial epilepsy, bipolar disorder (psychosis), and migraine therapy, sodium valproate is the first-line anticonvulsant. Therefore, this study aims to develop sodium valproate into a mucoadhesive buccal film dosage form using the solvent casting method. The preparations were then tested for antiepileptic activity, and the pharmacokinetic profile analysis was conducted in test animals induced with the pentylenetetrazole compound using a Post Randomized Controlled Group Design. The results showed an anti-epileptic activity with a longer duration of onset, shorter duration of seizures, and lower seizure frequency when compared to the experimental animal group administered sodium valproate tablets. The pharmacokinetic profile of sodium valproate included absorption parameters of Ka, Tmax, Cmax, Vd, T1/2 el, and Kel of 0.0033 Hr-1, 3.93 Hr-1, 4.55 mg/L, 3.03 L, 21.8 minutes, and 0.0053/minute, respectively. Based on the results, sodium valproate mucoadhesive buccal film preparation can be developed into an anti-epileptic preparation with a delayed release profile, and a relatively fast onset, making it a breakthrough for antiepileptic therapy.
http://impactfactor.org/PDF/IJCPR/14/IJCPR,Vol14,Issue4,Article8.pdf
Databáze: OpenAIRE